Synthetic Biologics, Inc.
(NYSE Amex Equities : SYN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.75%53.590.9%$1398.09m
JNJJohnson & Johnson 0.02%179.490.7%$1296.08m
BMYBristol-Myers Squibb Co. -2.64%75.551.0%$1180.29m
MRKMerck & Co., Inc. 0.19%92.490.7%$1169.17m
ABBVAbbVie, Inc. -1.23%148.721.9%$1086.85m
LLYEli Lilly & Co. 1.98%319.651.1%$986.32m
AZNAstraZeneca Plc 0.53%67.061.0%$494.16m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.15%143.400.0%$493.33m
NVSNovartis AG -0.06%91.210.2%$259.70m
GSKGlaxoSmithKline Plc -1.08%43.940.2%$254.81m
VERUVeru, Inc. 0.12%12.660.0%$254.11m
HZNPHorizon Therapeutics Plc 3.83%94.065.4%$203.54m
SGENSeagen Inc. 2.35%141.725.7%$190.04m
NVONovo Nordisk A/S 0.66%107.300.1%$184.06m
VTRSViatris, Inc. 1.54%12.200.0%$167.88m

Company Profile

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.